Surfactante pulmonar como tratamiento del distress respiratorio neonatal. Ambato, 2018-2019

Introduction: the pulmonary surfactant is a surfactant that is produced by type II pneumocytes of the alveolar epithelium, capable of decreasing the surface tension within the pulmonary alveoli, preventing them from collapsing during expiration Objectives: the use of pulmonary surfactant will be determined as a treatment in Respiratory Difficulty Syndrome in hospitalized newborns in the neonatology area of the Ecuadorian Institute of Social Security of the city of Ambato in the period September 2018 August 2019. Material and methods: This study will be of a descriptive, retrospective cross-sectional type by which newborns hospitalized in the neonatology department with a diagnosis of Respiratory Difficulty Syndrome that required surfactant use will be studied. Results: Of the 186 newborns admitted to the IESS Ambato neonatology service from September 2018 to August 2019, 24% were diagnosed with Respiratory Distress Syndrome of which 19 patients received pulmonary surfactant as treatment. Being prematurity as the most predisposing factor for this pathology. Conclusions: Pulmonary surfactant is an effective treatment for Respiratory Difficulty Syndrome, depending on the condition of the newborn and the predisposing factors for such pathology, the number of doses that will be needed to overcome the RDS should be taken into account, because some cases may require multiple doses (two or more). Keywords: Pulmonary surfactant, Respiratory Difficulty Syndrome, prematurity, prenatal glucocorticoids

• Главный автор: Maji Cando, Jimena Lisbeth (author)
• Другие авторы: Ñauñay Chicaiza, Jessica Viviana (author)
• Формат: bachelorThesis
• Язык: spa
• Опубликовано: 2019
• Предметы: Surfactante pulmonar; Síndrome de Dificultad Respiratoria,; glucocorticoides prenatales
• Online-ссылка: http://dspace.unach.edu.ec/handle/51000/6235